Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis

Bruno Vincenzi, Margherita Nannini, Elena Fumagalli, Giuseppe Bronte, Anna Maria Frezza, Delia De Lisi, Mariella Spalato Ceruso, Daniele Santini, Giuseppe Badalamenti, Maria Abbondanza Pantaleo, Antonio Russo, Angelo Paolo Dei Tos, Paolo Casali, Giuseppe Tonini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.

Original languageEnglish
Pages (from-to)69412-69419
Number of pages8
JournalOncotarget
Volume7
Issue number43
DOIs
Publication statusPublished - 2016

Fingerprint

Exons
Therapeutics
Mutation
Survival
sunitinib
Imatinib Mesylate

Keywords

  • Exon 11
  • GIST
  • Imatinib
  • Second line
  • Sunitinib

ASJC Scopus subject areas

  • Oncology

Cite this

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST : A retrospective analysis. / Vincenzi, Bruno; Nannini, Margherita; Fumagalli, Elena; Bronte, Giuseppe; Frezza, Anna Maria; De Lisi, Delia; Ceruso, Mariella Spalato; Santini, Daniele; Badalamenti, Giuseppe; Pantaleo, Maria Abbondanza; Russo, Antonio; Dei Tos, Angelo Paolo; Casali, Paolo; Tonini, Giuseppe.

In: Oncotarget, Vol. 7, No. 43, 2016, p. 69412-69419.

Research output: Contribution to journalArticle

Vincenzi, B, Nannini, M, Fumagalli, E, Bronte, G, Frezza, AM, De Lisi, D, Ceruso, MS, Santini, D, Badalamenti, G, Pantaleo, MA, Russo, A, Dei Tos, AP, Casali, P & Tonini, G 2016, 'Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis', Oncotarget, vol. 7, no. 43, pp. 69412-69419. https://doi.org/10.18632/oncotarget.5136
Vincenzi, Bruno ; Nannini, Margherita ; Fumagalli, Elena ; Bronte, Giuseppe ; Frezza, Anna Maria ; De Lisi, Delia ; Ceruso, Mariella Spalato ; Santini, Daniele ; Badalamenti, Giuseppe ; Pantaleo, Maria Abbondanza ; Russo, Antonio ; Dei Tos, Angelo Paolo ; Casali, Paolo ; Tonini, Giuseppe. / Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST : A retrospective analysis. In: Oncotarget. 2016 ; Vol. 7, No. 43. pp. 69412-69419.
@article{719e25055a684532a739ed2dd075e5a3,
title = "Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis",
abstract = "We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64{\%} received imatinib, 36{\%} sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95{\%} CI 9.7-10.9) and 5 months (95{\%} CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.",
keywords = "Exon 11, GIST, Imatinib, Second line, Sunitinib",
author = "Bruno Vincenzi and Margherita Nannini and Elena Fumagalli and Giuseppe Bronte and Frezza, {Anna Maria} and {De Lisi}, Delia and Ceruso, {Mariella Spalato} and Daniele Santini and Giuseppe Badalamenti and Pantaleo, {Maria Abbondanza} and Antonio Russo and {Dei Tos}, {Angelo Paolo} and Paolo Casali and Giuseppe Tonini",
year = "2016",
doi = "10.18632/oncotarget.5136",
language = "English",
volume = "7",
pages = "69412--69419",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "43",

}

TY - JOUR

T1 - Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST

T2 - A retrospective analysis

AU - Vincenzi, Bruno

AU - Nannini, Margherita

AU - Fumagalli, Elena

AU - Bronte, Giuseppe

AU - Frezza, Anna Maria

AU - De Lisi, Delia

AU - Ceruso, Mariella Spalato

AU - Santini, Daniele

AU - Badalamenti, Giuseppe

AU - Pantaleo, Maria Abbondanza

AU - Russo, Antonio

AU - Dei Tos, Angelo Paolo

AU - Casali, Paolo

AU - Tonini, Giuseppe

PY - 2016

Y1 - 2016

N2 - We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.

AB - We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.

KW - Exon 11

KW - GIST

KW - Imatinib

KW - Second line

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84994314496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994314496&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5136

DO - 10.18632/oncotarget.5136

M3 - Article

AN - SCOPUS:84994314496

VL - 7

SP - 69412

EP - 69419

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -